1. Introduction {#sec1}
===============

1.1. Epidemiology {#sec1.1}
-----------------

*Clostridium difficile* is a Gram-positive spore forming anaerobic bacterium that has become a significant problem in health care settings and in the community in recent years. It was recognized as an urgent threat to human health in a 2013 CDC report on antibiotic resistance.^[@ref1]^ Patients are susceptible to infection when there is a disturbance in the healthy gut microbiome, often due to prior oral antibiotic use, which permits *C. difficile* to colonize and cause disease in the gastrointestinal tract. *C. difficile* infection (CDI) severity varies from self-limiting mild diarrhea to severe life-threatening pseudomembranous colitis and toxic megacolon (inflamed colon with abdominal distension). The *C. difficile* glycosylating toxins, toxin A (TcdA) and toxin B (TcdB), are important virulence factors that promote epithelial tissue damage and inflammation in the infected host, resulting in rapid fluid loss into the intestinal epithelium and diarrhea.^[@ref2]^ Some strains produce an additional toxin, binary toxin or CDT. CDT is prevalent in strains commonly associated with severe disease, such as BI/NAP1/027 and ribotype 078 isolates, although the role of this toxin in disease remains undefined (review Gerding et al.^[@ref3]^).

*C. difficile* spores are an ideal vehicle for transmission between patients because they persist in the environment for long periods and are resistant to heat and typical disinfectants such as alcohol based hand washes.^[@ref4],[@ref5]^ Spores are ingested from the environment and germinate in response to bile salts in the small intestine. The resulting vegetative cells colonize the colon and produce toxins that cause disease symptoms.^[@ref2]^ An epidemic fluoroquinolone-resistant group of strains, belonging to the BI/NAP1/027 class, is associated with more severe disease and increased death rates^[@ref6]^ and has spread rapidly throughout hospitals and community care facilities at a global scale.^[@ref7]−[@ref9]^ Community acquired *C. difficile* infection (CA-CDI) rates have also increased with 40% of CA-CDI patients requiring hospitalization, providing a recurrent source of spores in hospitals and making complete eradication of the disease in hospitals a challenging task.^[@ref10]^

1.2. Current Antibiotic Therapies {#sec1.2}
---------------------------------

The first line treatment for *C. difficile* infection is antibiotics, either metronidazole **1** for mild to moderate infection or oral vancomycin **2** for moderate to severe infection (Figure [1](#fig1){ref-type="fig"}). Both of these drugs are generic and have been on the market for over 40 years.^[@ref11],[@ref12]^ Unfortunately in 14--27% of cases they do not effectively treat the infection or prevent relapsing infection.^[@ref13]^ Rifaximin **3** is sometimes used as a "chaser therapy", following initial treatment.^[@ref14]^ Fidaxomicin **4** (Figure [1](#fig1){ref-type="fig"}) is the first new drug on the market specifically designed to treat *C. difficile* and has been available since 2011. It offers improvements on relapse rates^[@ref15]^ by reducing collateral damage to the resident gut microbiota because it is more selective for *C. difficile*([@ref16],[@ref17]) over potentially beneficial bacteria, thereby encouraging the suppression of *C. difficile* colonization and proliferation, as well as purportedly inhibiting spore formation.^[@ref18]^

![Current antibiotic treatments primarily used to treat for *C. difficile* infection: metronidazole **1**, vancomycin **2**, rifaximin **3** (sometimes used as a chaser therapy), and fidaxomicin **4**.](jm-2014-016846_0002){#fig1}

### 1.2.1. Metronidazole {#sec1.2.1}

Metronidazole, a nitroimidazole, is active against a wide spectrum of anaerobic bacteria and parasites. Reduction of the nitro functional group in metronidazole initiates decomposition to toxic radical species. The nitro functional group scavenges electrons from electron carriers, such as reduced ferredoxin, which are at a lower reduction potential than their respective protein homologues in facultative anaerobic bacteria. Reduction forms an unstable nitro radical anion, which in most cases decomposes rapidly to nitrite.^[@ref19],[@ref20]^ This reduction consumes the compound and drives further uptake into the cell.^[@ref20]^ The nitrite and the radical imidazole that form cause damage to bacterial DNA leading to cell death.^[@ref20]^ An alternative nitro group reduction pathway via nitroso and hydroxylamine intermediates to the amine is less likely because of the high energy barrier of this process.^[@ref20]^ Oral metronidazole is essentially 100% bioavailable, with the systemic absorption resulting in reduced concentrations in the colon that approach the minimal inhibition concentration (MIC) in the colon.^[@ref21]^ The relatively low concentration of compound at the site of infection due to systemic absorption is thought to contribute to reduced efficacy in moderate to severe cases of CDI and toward the development of resistance.^[@ref22]^

### 1.2.2. Vancomycin {#sec1.2.2}

Vancomycin, a glycopeptide antibiotic, inhibits cell wall synthesis in Gram-positive bacteria by binding to cell wall building blocks. Specifically, vancomycin binds to the C-terminus of polypeptide intermediates terminating in [d]{.smallcaps}-alanyl [d]{.smallcaps}-alanine ([d]{.smallcaps}-Ala-[d]{.smallcaps}-Ala), particularly the peptidoglycan precursor lipid II.^[@ref23]^ This binding blocks transglycosylase enzymes from transferring the pentapeptide of lipid II to a polyglycan chain. Vancomycin can also bind to the pentapeptide on the polyglycan, inhibiting transpeptidases from linking adjacent pentapeptides to create the cross-linked framework of peptidoglycan.^[@ref23]^ Vancomycin is known to dimerize which increases the affinity to the [d]{.smallcaps}-Ala-[d]{.smallcaps}-Ala terminated pentapeptide.^[@ref24]^ Vancomycin is given orally and is minimally systemically absorbed, resulting in high concentrations achieved in the colon.^[@ref22]^ The broad-spectrum activity of vancomycin against Gram-positive bacteria contributes to a reduction in microbiome diversity compared to fidaxomicin treatment.^[@ref16]^

### 1.2.3. Rifaximin {#sec1.2.3}

The RNA synthesis inhibitor rifaximin is most commonly used to treat CDI as a chaser antimicrobial therapy after an initial dose of vancomycin. It is nonabsorbable and has minimal systemic effects. It is relatively selective on the gastrointestinal microbiota, although the concentrations of administered compound achieved in the gut are likely to cause inhibition of bacteria other than *C. difficile*.^[@ref25],[@ref26]^

### 1.2.4. Fidaxomicin {#sec1.2.4}

The macrolide fidaxomicin inhibits RNA synthesis by RNA polymerase. Unlike the broad-spectrum mechanisms of action of metronidazole and vancomycin, fidaxomicin shows a narrower spectrum of activity selective for *C. difficile* over other gut microbes.^[@ref27]^ Fidaxomicin also inhibits spore production,^[@ref18]^ with both effects believed to account for reduced relapse rates observed clinically. For example, in comparison to vancomycin, fidaxomicin had 52% fewer second occurrence relapse rates by 28 days after infection in patients with no prior episode of CDI (22.6% of vancomycin treated patients relapsed vs 11.7% of fidaxomicin treated patients).^[@ref15]^ A second meta-analysis reported a 40% reduction in persistent diarrhea, recurrence, or death over 40 days.^[@ref28]^ These figures demonstrate the improvement in clinical outcomes that can occur with a treatment specifically developed to target *C. difficile*. Nevertheless, there is still room for further improvement as fidaxomicin fails in 12% of treatments (in contrast to 14--27% treatment failures with vancomycin and metronidazole).^[@ref13],[@ref28]^ Fidaxomicin is minimally absorbed, which means systemic side effects are avoided despite its cytotoxicity, which is similar to tamoxifen against breast cancer cell lines.^[@ref29]^

1.3. Drug Resistance {#sec1.3}
--------------------

Metronidazole, vancomycin, and fidaxomicin drug resistance in *C. difficile* is not widespread at this time. However, resistance has been observed and is of concern given the increased prevalence of *C. difficile* infections over the past decade and the subsequent requirement for antibiotics now and in the future.^[@ref30]−[@ref32]^ Metronidazole resistance of \>32 μg/mL has been reported, but resistance is unstable and is often lost on passaging or freeze--thawing of bacteria.^[@ref30],[@ref33],[@ref34]^ The MIC values observed of \>32 μg/mL are likely outside the therapeutic concentrations achieved in the colon, since the concentration of metronidazole in the feces of patients with CDI has been found to be 0.8--24.2 μg/g of stool.^[@ref21]^ Reduced susceptibility to vancomycin has been seen, with *C. difficile* isolates with a MIC of 4 μg/mL reported (compared to sensitive strains with MIC range of ≤0.5--2 μg/mL).^[@ref31]^ In clinical trials fidaxomicin resistance up to 16 μg/mL was observed, a significant increase over the normal MIC range of 0.003--1 μg/mL.^[@ref35]^ The MIC of fidaxomicin increased to 2 μg/mL against *C. difficile* in a 13-generation forced resistance study.^[@ref36]^ For fidaxomicin, like the rifamycin antibiotics, single amino acid substitutions in the protein targets cause high resistance (MIC \> 256 μg/mL), rendering the antibiotic ineffective.^[@ref37]^ The clinical relevance of elevated MICs to vancomycin and fidaxomicin is unclear given the high concentrations (generally \>1000 μg/g) achieved in the feces.^[@ref38],[@ref39]^ However, considering the relative ease that *C. difficile* strains have spread globally, any development of resistance is of concern, particularly if no other new drugs are approved for *C. difficile*. Therefore, continued investment into the development of new antimicrobials is important to mitigate the potential for development and spread of resistance to the current arsenal of antibiotics.

1.4. Alternative Treatments for Severe CDI: Fecal Bacteriotherapy {#sec1.4}
-----------------------------------------------------------------

Fecal bacteriotherapy is used to treat relapsing or severe CDI that is refractory to treatment with antibiotics and acts to restore balance to the gut microbiota in order to suppress *C. difficile* outgrowth. Typically patients are given antibiotics to reduce the load of actively growing *C. difficile*, with antibiotic treatment withheld 2--3 days prior to transplant of homogenized donor feces into the colon through a nasogastric intubation, enema, or colonoscope.^[@ref40]^ This therapy is psychologically unappealing and also poses risks in terms of infection from the donor and from the irrigation and colonoscopy procedures performed prior to the transplant.^[@ref41]^ Despite these drawbacks, fecal bacteriotherapy is gaining popularity because of the reported success rate of 92% (systematic review by Gough et al.^[@ref42]^). In light of the potential benefits, patient acceptance is high with 94% of patients surveyed indicating that they would accept treatment over antibiotics if recommended by a doctor.^[@ref42]−[@ref44]^

Despite evidence of fecal bacteriotherapy being performed since the 4th century during the Dong-Jin dynasty in China,^[@ref45],[@ref46]^ the first randomized controlled clinical trial for treatment of *C. difficile* was only reported in 2013.^[@ref41]^ This rudimentary treatment is moving toward a refined, standardized practice supported by a hospital based prescreened donor system, with ongoing investigations into frozen fecal preparations and case studies of "designer" synthetic fecal transplants incorporating 33 strains of laboratory cultured bacteria.^[@ref41],[@ref47]−[@ref49]^ A standardized laboratory preparation is considerably more palatable, controllable, safer, and marketable, since strains can be sequenced and antibiotic resistant strains or other pathogenic organisms avoided. However, further research is required to ensure longevity of treatment and that laboratory passage does not reduce strain efficacy.^[@ref50]^

Medical protocols are reported in the literature,^[@ref51],[@ref52]^ but do-it-yourself guides^[@ref53]^ and YouTube "how to" videos are directly accessible to patients online. In response to this, in April 2013 the FDA moved to regulate fecal bacteriotherapy as a biological therapy and thus require that physicians file an IND before performing fecal transplant.^[@ref54]^ However, acknowledgment that this would potentially deny patients a life-saving cure saw an update on this ruling in July 2013, with fecal transplants to treat CDI permitted on compassionate grounds without an IND under an "enforcement discretion" as long as informed consent is obtained with appropriate acknowledgment of risks of the investigational therapy.^[@ref55]^ In March 2014 these guidelines were tightened so that the donor must be known to the physician or the provider and that the donor sample be screened under the direction of the provider.^[@ref56]^ Fecal bacteriotherapy also faces further regulatory issues, with recent debate over whether the treatment should be classified as an investigational new drug or tissue.^[@ref56],[@ref57]^

2. Clinical Development {#sec2}
=======================

The clinical pipeline for new *C. difficile* treatments is characterized by traditional antibiotic molecules and nonantibiotic biological therapeutics (recently reviewed by Tsutsumi^[@ref58]^) at various stages of development (Figure [2](#fig2){ref-type="fig"}, Table [1](#tbl1){ref-type="other"}).

![Antibiotics in clinical trials to treat CDI.](jm-2014-016846_0003){#fig2}

###### Clinical Pipeline for *C. difficile* Treatment Includes Antibiotics and Nonantibiotic Therapies at Each Phase of Development

  compd                               phase                                 developer                                                                    class                                 ref
  ----------------------------------- ------------------------------------- ---------------------------------------------------------------------------- ------------------------------------- ----------------------
  **Antibiotic therapies**                                                                                                                                                                     
  CRS3123, **5**                      I                                     National Institute of Allergy and Infectious Diseases (NIAID)                methionyl-tRNA synthetase inhibitor   ([@ref59])
  NVB302, **6**                       I                                     Novacta Biosystems Limited                                                   lantibiotic                           ([@ref60])
  SMT19969, **7**                     II                                    Summit Corporation Plc./Wellcome Trust                                       bis-benzimidazole                     ([@ref63])
  LFF571, **8**                       II                                    Novartis Pharmaceuticals                                                     4-aminothiazolyl macrocycle           ([@ref62])
  cadazolid, **9**                    III                                   Actelion                                                                     quinolonyloxazolidinone               ([@ref64])
  ramoplanin, **10**                  II (previously completed phase III)   Nanotherapeutics, Inc.                                                       lipoglycodepsipeptide                 ([@ref65])
  rifaximin, **3**                    III                                   Salix Pharmaceuticals                                                        rifamycin                             ([@ref166])
  CB-183,315, **11**                  III                                   Cubist Pharmaceuticals                                                       lipopeptide                           ([@ref67], [@ref68])
  nitazoxanide, **13**                III                                   VA Medical Center, Houston/Baylor College of Medicine                        nitrothiazolide                       ([@ref70])
  **Nonantibiotic therapies**                                                                                                                                                                  
  IC84                                I                                     Valneva Austria GmbH                                                         vaccine                               ([@ref72])
  frozen encapsulated FMT             I                                     Massachusetts General Hospital                                               microbiota restoration                ([@ref167])
  frozen FMT                          I                                     Massachusetts General Hospital                                               microbiota restoration                ([@ref168])
  defined FMT                         I                                     Baylor College of Medicine/Michael Debakey Veterans Affairs Medical Center   microbiota restoration                ([@ref169])
  PF-06425090                         II                                    Pfizer                                                                       vaccine                               ([@ref170])
  VP20621                             II                                    Shire                                                                        nontoxigenic *C. difficile*           ([@ref75])
  GS-CDA1, MDX-1388                   II                                    University of Massachusetts, Worcester/Medarex                               human monoclonal antibodies           ([@ref171])
  FMT                                 II                                    NorthShore University HealthSystem                                           microbiota restoration                ([@ref172])
  FMT in pediatric patients           II                                    MemorialCare Health System                                                   microbiota restoration                ([@ref173])
  FMT                                 II                                    Colleen Kelly, The Miriam Hospital                                           microbiota restoration                ([@ref174])
  FMT by colonoscopy                  II                                    Catholic University of the Sacred Heart                                      microbiota restoration                ([@ref175])
  RBX2660                             II                                    Rebiotix Inc.                                                                microbiota restoration                ([@ref80])
  tolevamer (GT267-004)               III                                   Genzyme                                                                      toxin binder                          ([@ref73])
  MK-3415, MK-6072, and MK-3415A      III                                   Merck                                                                        human monoclonal antibodies           ([@ref74])
  ACAM-CDIFF                          III                                   Sanofi-Pasteur                                                               vaccine                               ([@ref71])
  Bio-K+ CL-1285                      III                                   Bio-K Plus International Inc.                                                microbiota restoration                ([@ref79])
  FMT by capsule versus colonoscopy   II/III                                University of Alberta/University of Calgary                                  microbiota restoration                ([@ref176])

2.1. Traditional Antibiotics in the Clinical Pipeline {#sec2.1}
-----------------------------------------------------

Several new antibiotics have entered the first stage of human clinical testing, phase I, including **5** (CRS3123, previously known as REP3123), a methionyl-tRNA synthetase inhibitor being developed by the National Institute of Allergy and Infectious Diseases.^[@ref59]^ A type B lantibiotic deoxyactagardine B, **6** (NVB302), under development by Novacta Biosystems has completed phase I.^[@ref60]^ Summit Corporation is recruiting for proof of efficacy phase II clinical trials of their bis-benzimidazole **7** (SMT19969),^[@ref61]^ while Novartis has completed phase II trials of their 4-aminothiazolyl macrocycle **8** (LFF571).^[@ref62],[@ref63]^ Acetlion's cadazolid **9**, a quinolonyloxazolidinone chimeric antibiotic, is recruiting for pivotal phase III testing.^[@ref64]^ Ramoplanin **10**, a lipoglycodepsipeptide antibiotic acquired from Oscient Pharmaceuticals by Nanotherapeutics^[@ref65]^ has completed a phase III trial for CDI and will be conducting a phase IIb study for relapse prevention.^[@ref66]^ A lipopeptide analogue of daptomycin, **11** (CB-183,315) under development by Cubist, is currently recruiting for phase III.^[@ref67],[@ref68]^ Two existing drugs are undergoing repurposement trials: the glycycline antibiotic tigecycline **12** (phase unknown)^[@ref69]^ and nitazoxanide **13** (phase II),^[@ref70]^ a drug currently used to treat protozoan infections.

2.2. Nonantibiotic Therapies in the Clinical Pipeline {#sec2.2}
-----------------------------------------------------

In addition to new antibiotic drug candidates for treatment of *C. difficile* infection, there are numerous biotherapeutic approaches at each phase of the clinical pipeline. Unlike antibiotic-based therapies, several of these approaches target the *C. difficile* major toxins, TcdA and TcdB, and include active and passive vaccine treatments to boost the immune response. A Sanofi-Pasteur ACAM-CDIFF TcdA- and TcdB-toxoid vaccine in phase III is the most advanced in the clinical pipeline.^[@ref71]^ Pfizer and Intercell (IC84) both have vaccine candidates in phase I, both utilizing recombinant toxin-based approaches.^[@ref72]^ Another treatment approach tested the ability of polymers to bind the disease-causing toxins secreted during *C. difficile* vegetative growth, thereby reducing inflammation and severe disease symptoms. Unfortunately, the polymer tolevamer failed to meet efficacy end points in phase III trials and was inferior to metronidazole and vancomycin antibiotic treatment.^[@ref73]^ Merck's human monoclonal antibodies (MK-3415, MK-6072, and MK-3415A), for use in a passive immunotherapeutic approach by inactivating the toxins, are in phase III trials.^[@ref74]^

CDI is considered a secondary infection resulting from an initial disruption in the healthy microbial gut microbiota, often caused by antibiotic use. Therefore, another therapeutic approach aims to correct or prevent dysbiosis by manipulating the microbial niche. Treatment with nontoxigenic *C. difficile* strains, which aims to outcompete toxigenic strains and prevent their colonization, is in phase II trials, by ViroPharma (acquired by Shire in 2013).^[@ref75]^ However, the *C. difficile* toxin-encoding PaLoc region from a toxigenic strain was recently shown to be mobilized to nontoxigenic isolates, supporting the hypothesis that nontoxigenic strains can become toxigenic through horizontal gene transfer events.^[@ref76]^ This raises concerns that the use of live nontoxigenic strains in therapeutic approaches is risky, especially since a number of placebo patients were also found to be infected with nontoxigenic *C. difficile* strains during the clinical trials, apparently because of spore contamination of communal living areas.^[@ref77]^ There are also ethical considerations surrounding the use of this approach, since carriers may transmit the strain to nonconsenting individuals. An alternative approach in the future could be the use of *Clostridium scindens*, since it has recently been shown to promote resistance to *C. difficile* infection in mouse CDI models in a manner associated with increased production of *C. difficile*-inhibiting secondary bile metabolites.^[@ref78]^

Another option under consideration is the use of probiotic therapies to prevent CDI. Bio-K+ CL-1285 is an encapsulated probiotic propriety mixture of *Lactobacillus acidophilus* and *Lactobacillus casei* that has completed phase III clinical trials for prevention of antibiotic-associated diarrhea, including CDI.^[@ref79]^ Patients at high-risk of developing CDI (50--70 years age, receiving penicillin, cephalosporin, or clindamycin antibiotic therapy), administered two capsules of Bio-K+ CL-1285 daily, were significantly less likely to develop CDI (23.8% placebo vs 1.2% twice daily capsule treatment, *P* = 0.002), suggesting that this approach may be efficacious.^[@ref79]^

As discussed earlier, microbiota transplantation also aims to restore an imbalanced microbiota using a holistic strategy. Fecal transplant therapies or artificial microbial preparations containing a diverse microbial ecosystem are used in this approach. Clinical trials are currently evaluating issues such as whether frozen and thawed or encapsulated preparations are as effective as the fresh, unprocessed material, since many bacteria, particularly anaerobes, would not survive the treatment and storage phase, perhaps reducing product efficacy compared with the starting material. The aim is to make this therapy easier to distribute, as set donations can be processed, tested for pathogens, prepared ahead of time, and made more palatable by encapsulation of the transplant. A recent 2014 study indicates that frozen capsules are indeed a viable form of administration.^[@ref49]^ Rebiotix have focused on developing an off the shelf product for transplant that is consistent and easy to administer. Their product, RBX2660, is a microbial suspension, which has completed enrollment in phase II, and Rebiotix is in discussions with the FDA on design of the phase III trial.^[@ref80]^ Monarch Labs in collaboration with BioTherapeutics, Education and Research Foundation is also seeking to develop a fecal transplant therapy, Medical Microbiota, which is a prescreened, cGMP processed product for transplantation. They are also developing a cGMP processing and banking service for autologous transplantation.^[@ref81]^

An important factor that may influence the efficacy of microbiota-restoration strategies is the treatment of patients with broad-acting antibiotics such as vancomycin to control CDI, although antibiotics are generally halted shortly prior to administration of microbiota therapy.^[@ref52]^ Antibiotic therapy reduces the load of vegetative *C. difficile* cells in the host prior to infusion of the microbial suspension, which may contribute to the subsequent success of microbiota restoration strategies. However, the necessity of this antibiotic therapy prior to the application of microbial restoration therapies is not known.^[@ref52]^ It is clear that the need for antibiotics for the treatment of CDI will continue and that their adjunct use in microbial restoration therapies may be highly beneficial. For this reason, there is a continued market for investment into the development of new antimicrobials against CDI, which will be the focus of the remainder of this review.

3. Early Drug Discovery Research and Preclinical Development Pipeline {#sec3}
=====================================================================

We have undertaken a chemoinformatic approach to understand the historical and recently explored chemical space for compounds with antimicrobial activity against *C. difficile* at the preclinical stages of drug research and discovery. Compounds with reported antimicrobial activity against *C. difficile* were abstracted from the ChEMBL^[@ref82]^ database. The data were then separated into either known, marketed antibiotics or compounds at the early discovery research phase and preclinical stages of development. The compounds in the early preclinical drug discovery phase were clustered using Pipeline Pilot into antimicrobial classes (Figure [3](#fig3){ref-type="fig"}, methods in [Supporting Information](#notes-2){ref-type="notes"}). Analysis of the data from ChEMBL showed that the results only contained compounds published in four scientific journals over selected years: *Antimicrobial Agents and Chemotherapy* (2007--2010), *Bioorganic Medicinal Chemistry* (one article from 2008), *Bioorganic Medicinal Chemistry Letters* (1998--2012), and *Journal of Medicinal Chemistry* (1984--2009). Therefore, the search was widened to include all bioactivities against *C. difficile* catalogued in the Reaxys Medicinal Chemistry Public Beta as well as manual searches of the literature.

![Compounds in early and preclinical drug discovery phase with antimicrobial activity against *C. difficile* in the scientific literature from the analysis of compounds with antimicrobial activity against *C. difficile* curated by ChEMBL. Antibiotics on the market and agents in clinical trials were excluded from analysis.](jm-2014-016846_0004){#fig3}

The majority of studies are 10--20 years old and predate the *C. difficile* crisis of the past decade. However, the more recent studies that include *C. difficile* as a greater focus demonstrate the renewed drug discovery efforts for this pathogen. Notably, few of the older studies are focused on medicinal chemistry efforts to specifically optimize compounds for activity against *C. difficile*. However, the tiacumicin family of antibiotics, including fidaxomicin, was initially discovered in 1975 but the development of this class remained largely unexplored until the late 1990s when Optimer Pharmaceuticals initiated the commercial development of fidaxomicin for CDI.^[@ref29]^ Therefore, examining the past can offer direction for future investigations, especially since most of the older research was not conducted in the context of the requirements for a *C. difficile*-specific antibiotic.

The majority of the reports describe investigations of traditional antibiotic chemotypes with screening against *C. difficile* performed in parallel to testing against other bacterial pathogens that form the focus of these studies. These studies are summarized in [Supporting Information Table 1](#notes-2){ref-type="notes"}. Of note is the importance of testing drug candidates against a number of strains, since there is a wide range of MIC results for some drug candidates. The MIC~50~ and MIC~90~ values are important to the interpretation of the MIC ranges obtained from testing against multiple strains and thus determining the efficacy against a population of strains. The discussion here focuses on studies where a number of analogs were synthesized and on studies of unique chemotypes tested against *C. difficile*.

3.1. Nitroheterocycles {#sec3.1}
----------------------

Ballard et al. have explored analogs of the nitrothiazole drug, nitazoxanide **13**, for activity against *C. difficile* as part of a broader study for compounds with activity against *Helicobacter pylori* (Figure [4](#fig4){ref-type="fig"}A).^[@ref83]^ Variations to the thiophene and thiazole "head" groups **14**--**16** and amide "tail" **a**--**e** (Figure [4](#fig4){ref-type="fig"}A)^[@ref83]^ were found to influence activity with MICs varying from 0.4 to \>28 μM. The headgroup **15** found in nitazoxanide was generally favored, with **15c** and **15d** the most potent against *C. difficile* (MICs of 0.4 and 1 μM, respectively). A follow-up study explored tail group **f**--**l** and headgroup **15** to give MICs ranging from 0.8 to 5.9 μM (Figure [4](#fig4){ref-type="fig"}A).^[@ref84]^ Four furylthiazoles (no nitro group) **17**--**22** and two phenylthiazoles **21**--**22** also developed for *H. pylori* by Fujisawa Pharmaceutical Co. were tested for activity against *C. difficile* but were not active at 100 μg/mL (Figure [4](#fig4){ref-type="fig"}B).^[@ref85]−[@ref87]^ In contrast, two of five thiazolides, **23** and **24**, only those with a nitrothiazole ring similar to nitazoxanide, displayed potent activity (0.06--0.5 and 0.06--0.25 μg/mL, respectively) against 10 strains of *C. difficile*.^[@ref88]^ The three inactive compounds **25**--**27** (MIC \> 32 μg/mL) either contained no nitro group (denitrotizoxanide) **25** or a bromine in place of the nitro group (**26** and **28**) (Figure [4](#fig4){ref-type="fig"}C).^[@ref88]^

![Nitroheterocycles: (A) analogs of nitazoxanide **14**--**16**;^[@ref83],[@ref84]^ (B) furanyl thiazoles **17**--**20** and phenylthiazoles **21** and **22** (inactive against *C. difficile*, MIC \> 100 μg/mL);^[@ref85]−[@ref87]^ (C) thiazolides with a nitrothiazole ring, similar to nitazoxanide;^[@ref88]^ (D) nitrofuranylsemicarbazone **28**;^[@ref89]^ (E) the six 5-nitroimidazole scaffolds **29**--**34** in the library of metronidazole triazole conjugates (crude, \>85% purity);^[@ref90]^ (F) quinoxalines **35**--**36**.^[@ref92]^](jm-2014-016846_0005){#fig4}

A series of nitrofuranylsemicarbazones were investigated for MIC activity against *C. difficile*, *Staphylococcus epidermis*, *Staphylococcus aureus*, methicillin resistant *S. aureus*, and *Propionibacterium acnes* (Figure [4](#fig4){ref-type="fig"}D).^[@ref89]^ Only compound **28** had reasonable activity against four strains of *C. difficile*, in the range of 0.25--8 μg/mL, with the other 11 compounds in the range of 32 to \>256 μg/mL. While the mechanism of action of nitrofuryls is typically attributed to toxicity caused by reduction of the nitro group,^[@ref89]^ the role of this mechanism in this case is unclear as several matched pairs with R~2~ = H or NO~2~ did not show large differences in activity. The R~1~ groups (methyl, isopropyl, and *tert*-butyl) are likely too far from the nitrofuranyl to affect the reduction process electronically, so they should not cause changes in activity based on a reduction mechanism. Additionally the active compound shows similar activity against the other bacteria assayed, presumably under aerobic conditions, further supporting an alternative mechanism of action for this compound.

The chemical space for nitroheterocyclic compounds with a reduction-based mode of action similar to metronidazole remained relatively unexplored for *C. difficile* until a series of metronidazole triazole conjugates was published in 2013 (Figure [4](#fig4){ref-type="fig"}E).^[@ref90]^ This group synthesized six 5-nitroimidazole azido cores and reacted each core with a library of 63 structurally diverse alkynes to make 378 5-nitroimidazole triazole conjugates **29**--**34**.^[@ref90]^ These compounds were tested as crude mixtures (purity of \>85% by LCMS) against *C. difficile*, *H. pylori*, *Trichomonas vaginalis*, *Giardia lamblia*, and *Bacteroides fragilis*. A second follow-on series of 47 different alkynes reacted with the six cores gave a further 281 compounds, but these were not tested against *C. difficile*.^[@ref90]^ Interestingly, a high proportion of the compounds in the initial series were active against metronidazole resistant *G. lamblia* (100% of compounds tested) and *T. vaginalis* (47% of compounds tested) parasite strains. However, the compounds generally lost activity against the microaerophilic bacterium *H. pylori* containing mutations in both the *frxA* and *rdxA* genes that encode reductases involved in the clinical resistance to metronidazole (only 1.4% of compounds active).^[@ref90],[@ref91]^ This suggests that some metronidazole triazole conjugates may be active against metronidazole resistant *C. difficile*. However, the effectiveness of these compounds at inhibiting spore formation, germination, and spore outgrowth is not currently known.

The quinoxalines **35** (SC44914) and **36** (SC-44942-A) have a similar spectrum of action as metronidazole, with the mode of action postulated to be similar because of similar reduction potentials (Figure [4](#fig4){ref-type="fig"}F).^[@ref92]^ Both quinoxalines were potent against *C. difficile* with MICs against 20 isolates of ≤0.06 μg/mL for **35** and ≤0.06 to 0.5 μg/mL for **36** (the metronidazole control was ≤0.06 to 2 μg/mL).^[@ref92]^

3.2. Glycopeptides {#sec3.2}
------------------

Zhang et al.^[@ref93]^ made a series of desmethyl vancomycin analogs **37**--**53** inspired by telavancin and oritavancin, glycopeptides approved for treatment of complicated skin infections (Figure [5](#fig5){ref-type="fig"}). This series of compounds contained desmethyl vancomycin in which the methyl group on the amino group of the *N*-terminal residue of vancomycin was absent. Various hydrophobic groups were appended via the amine on the vancosamine sugar (R~1~ of Figure [5](#fig5){ref-type="fig"}), in a fashion similar to the hydrophobic chains on oritavancin and telavancin. When tested for potency against *Enterococcus faecium* and *C. difficile,* the compounds were generally within one dilution of the MICs for the controls (vancomycin and desmethyl vancomycin) for four strains of *C. difficile*, indicating that variations at these positions do not play a key role in determining activity for *C. difficile*. This was in contrast to variation observed in the structure--activity relationships for *E. faecium.*

![Desmethyl vancomycin derivatives **37**--**53** with lipophilic variations at R~1~ on the vancosamine sugar.^[@ref93]^](jm-2014-016846_0006){#fig5}

3.3. Macrolides {#sec3.3}
---------------

Kirst et al. reported on macrolide antibiotics related to tylosin natural products and synthetically modified derivatives from Eli Lilly Research Laboratories (Figure [6](#fig6){ref-type="fig"}).^[@ref94]^ The compounds were tested against a wide range of aerobic and anaerobic bacteria. Fifteen of these compounds **54**--**68** were tested for activity against *C. difficile*.^[@ref94]^ Six compounds of the desmyocosin scaffold **58**--**64** showed a MIC of ≤0.5 μg/mL compared with the desmycosin **57** MIC of 0.25 μg/mL. These compounds were also active against a range of anaerobic bacterial strains including *B. fragilis*, *Fusobacterium symbiosum*, *Peptococcus prevoti*, and *Peptostreptococcus anaerobius*, as well as aerobic bacterial strains including *S. aureus* and *Streptococcus* group B, C, and D strains. Three tylosin derived macrocycles also showed good activity at ≤0.5 μg/mL compared to 1 μg/mL for tylosin **54**.

![Tylosin derived macrolides **54**--**69**.^[@ref94]^](jm-2014-016846_0007){#fig6}

The 23-demycinosyltylosin (DMT) derivative **68** also showed good activity against *C. difficile* (1 μg/mL) with the 5-*O*-myc-aminosyltylonolide (OMT) **65** and OMT derivatives **66** and **67** showing weaker activity at 2--4 μg/mL (Figure [6](#fig6){ref-type="fig"}).^[@ref94]^ The majority of these compounds were tested using in vivo models, against either *Streptococcus pyogenes* or *S. aureus*. The goal of this study was to improve the oral availability of these compounds by chemical modifications. The compounds were dosed subcutaneously and orally. Several compounds lost activity when dosed orally compared to subcutaneous dosing. Peripheral plasma compound levels measured in mice and rats supported the varied oral bioavailability. This study is an example where drug candidates that failed in the past because of properties such as poor oral availability may now be useful in the treatment of *C. difficile*, where compounds with poor oral availability are desirable for *C. difficile* treatment because a high concentration of compound remains at the site of infection, with low systemic exposure.

A more recently developed tylosin macrolide **69** (YM133) exhibited potent activity against 21 *C. difficile* strains with MICs ranging from ≤0.05 to 0.39 μg/mL (Figure [6](#fig6){ref-type="fig"}).^[@ref95]^ Compound **69** was also active against macrolide-resistant *S. aureus* but was less active against strains with 14- and 16-membered macrolide resistance compared to 14-membered macrolide resistant or erythromycin resistant strains.^[@ref95]^

3.4. Fluoroquinolones {#sec3.4}
---------------------

A large number of fluoroquinolones **70a**--**m**, **71a**--**f**, **72a**--**g**, and **73a**--**c** were synthesized and investigated for antibacterial activity by Sanchez et al. from Parke-Davis as a division of Warner-Lambert Pharmaceuticals (now acquired by Pfizer) (Figure [7](#fig7){ref-type="fig"}).^[@ref96]^ As a part of this study, 27 compounds were tested against several anaerobic bacteria including *C. difficile*. The compounds ranged in activity from 0.2 to 12.5 μg/mL, with the most potent series **70a**--**m** containing R~1~ = H, R~2~ = OMe, and R~3~ = variety of piperazine, pyrrolidine, and piperidine groups (Figure [7](#fig7){ref-type="fig"}).^[@ref96]^ While *C. difficile* potency was good, the compounds possessed poor specificity, with broad spectrum activity against Gram-negative and Gram-positive facultative anaerobic bacteria and obligately anaerobic bacteria.^[@ref96]^

![Fluoroquinolones **70**--**73**.^[@ref96]^](jm-2014-016846_0008){#fig7}

3.5. Tetramic and Tetronic Acids {#sec3.5}
--------------------------------

Tetramic acids have been shown to have activity against *C. difficile* (Figure [8](#fig8){ref-type="fig"}). Aromatic dienoyltetramic acids **74**--**77** formed the basis of a study by Rosen et al. of Abbott Laboratories.^[@ref97]^ The compounds' activity ranged from 125 to ≤0.5 μg/mL. The derivatives active at ≤0.5 μg/mL generally contained a longer C~10~H~7~ lipophilic tail. More recently, Ueda et al. examined tetramic acids, derived from bacterial autoinducers, for their bactericidal activity against *C. difficile*.^[@ref98]^ Compound **78** at 10 μM (2.5 μg/mL) reduced *C. difficile* numbers to the limit of detection of 2 log CFU/mL after overnight incubation.^[@ref98]^ The other tetramic acids tested **79**--**82** with lower activity (13--15 μg/mL) showed that the keto--enol form with the free hydroxyl group and a longer acyl side chain is important to maintain activity against *C. difficile*, since tetramic acids lacking these features were inactive at 100 μM (21--31 μg/mL).^[@ref98]^ The tetramic acids, tirandalydigin **83** (MIC = 32 μg/mL), streptolydigin **84** (8 μg/mL), and tirandamycin **85** (16 μg/mL), were weakly active against one strain of *C. difficile*.^[@ref99]^ The agglomerins A, B, C, and D **86**--**89**, tetronic acids structurally related to tetramic acids, were reported by Shoji et al. at Shionogi & Co. with activity against *C. difficile* from 0.78 to 3.13 μg/mL.^[@ref100]^ The structures were solved in 1990 by Terui et al.^[@ref101]^

![(A--C) Tetramic acids **74**--**85** investigated for activity against *C. difficile*([@ref87],[@ref97],[@ref98]) and (D) structurally related tetronic acids **86**--**89**.^[@ref100]^](jm-2014-016846_0009){#fig8}

3.6. Bis-Indoles {#sec3.6}
----------------

The bis-indoles **90** (MBX 1066) and analogue **91** (MBX 1162) (Figure [9](#fig9){ref-type="fig"}) investigated by Microbiotix Inc. have broad spectrum activity against Gram-positive and Gram-negative aerobic and anaerobic bacteria including 18 isolates of *C. difficile* (MIC~90~ for both compounds was 0.12 μg/mL).^[@ref102]^ The compounds inhibit DNA synthesis and are proposed to bind in the minor groove of the DNA duplex because of their similarity to DNA binding agents.^[@ref103]^ The bisindole structure is important for activity against *C. difficile* since a 2-phenyl-1*H*-indole **92** tested against three *C. difficile* strains was inactive at the highest concentration tested (100 μg/mL).^[@ref104]^

![Bis-indoles **90** and **91** with potent activity against *C. difficile* compared to the 2-phenyl-1*H*-indole **92** not active at 100 μg/mL.^[@ref102],[@ref104]^](jm-2014-016846_0010){#fig9}

3.7. Hybrids {#sec3.7}
------------

Hybrid-like 1-carba-3-thiathiazole cephalosporins were investigated by Eli Lilly for their activity against anaerobic bacteria (Figure [10](#fig10){ref-type="fig"}A).^[@ref105]^ Five compounds **93**--**97** were reported with thiazoles at the 3-thia positions and either a methyloxime **94**--**97** or fluoroethyloxime **93** side chain.^[@ref105]^ The compound derivatives with a nitrothiazole and a methyloxime **94** or fluoroethyloxime side chain **93** exhibited broad spectrum activity against the panel of anaerobes tested which was generally equivalent to or better than cefoxitin and cefotetan controls. They were active at 2 and 4 μg/mL against *C. difficile* (cefoxitin, 32 μg/mL; cefotetan, 16 and 32 μg/mL). Thiazole ring substitutions **95**--**97** were tolerated, and the compounds had similar activity against the aerobic organisms: *S. aureus*, *S. epidermis*, *Streptococcus pneumoniae*, *Haemophilus influenza*, *Escherichia coli*, and *Enterobacter aerogenes*.

![(A) Hybrid 1-carba-3-thiathiazole cephalosporins^[@ref105]^**93**--**97** and (B) hybrid penem and carbapenems linked to quinolones **98**--**101**.^[@ref106]^](jm-2014-016846_0011){#fig10}

Attempts were made to replace the nitro group on the thiazole because of observed mutagenicity. Methyl sulfoxide **95**, nitrile **96**, or trifluoromethyl **97** groups increased the activity against *C. difficile* (MICs of 0.06--0.125 μg/mL). However, loss of the nitro-substituted thiazole resulted in loss of activity against *Bacteroides* spp. and *F. symbiosum*, which the researchers deemed as a negative feature in their search for a broad-spectrum agent. Given that *C. difficile* infection is exacerbated by damage to the gut microbiota, selective agents are now considered desirable. This illustrates the potential value of re-examining drug candidates abandoned in the past because of their lack of broad-spectrum action, as this selectivity is now considered an advantage.

Another example of hybrid compounds is the Hoffmann-La Roche study by Corraz et al. into penems and carbapenems linked at the 2′ position to quinolones (Figure [10](#fig10){ref-type="fig"}B).^[@ref106]^ Four hybrid compounds **98**--**101** were tested against either one or in some instances two strains of *C. difficile*. The hybrid compounds showed superior MIC activity (0.5--8 μg/mL) against *C. difficile* when compared to the single antibiotic counterparts (fleroxacin, ciprofloxacin, or imipenem, 4--16 μg/mL). However, in general the hybrid compounds had superior MICs against a broad range of other Gram-negative and Gram-positive bacteria, indicating that these are not good leads to pursue for new selective agents against *C. difficile*.

3.8. Other DNA Topoisomerase and Gyrase Inhibitors {#sec3.8}
--------------------------------------------------

Both synthetic inhibitors and natural products that target topoisomerase II, inhibiting DNA synthesis, have been reported (Figure [11](#fig11){ref-type="fig"}). Dual acting inhibitors of bacterial DNA gyrase and topoisomerase IV, based on an aminobenzimidazole urea core, have been extensively explored by Vertex Pharma as new leads against a range of Gram-positive pathogens (staphylococci, streptococci, and enterococci) and the respiratory Gram-negative pathogen *H. influenzae*.^[@ref107]^ Two lead compounds, **102** (VRT-125853) and **103** (VRT-752586), showed relatively low frequencies of spontaneous resistance.^[@ref107]^ Compound **103** was active in *S. aureus* and *S. pneumoniae* animal infection models.^[@ref108]^ When tested for in vitro activity against *C. difficile*, **102** displayed a range of potencies against 11 strains of *C. difficile* (1--16 μg/mL), while **103** was found to be even more potent (0.06--4 μg/mL).^[@ref107]^ Further development of the aminobenzimidazole urea compound class by Vertex has alleviated deficiencies identified for **103** such as CYP3A4 inhibition, reactive metabolite formation, short half-life, and poor physicochemical properties, and **104** has been selected as a preclinical candidate.^[@ref109]^ However, the activities of **104** and other analogs against *C. difficile* have not been reported. The Vertex library of aminobenzimidazoles (\>330 compounds)^[@ref110]^ prepared could be reinvestigated to potentially identify alternative lead compounds with potent, more selective activity against *C. difficile* and poor oral availability.

![Aminobenzimidazole urea inhibitors of bacterial DNA gyrase and topoisomerase IV **102**--**104**,^[@ref107],[@ref109]^ topoisomerase II ATPase inhibitor kibdelomycin **107**,^[@ref112]^ and benzothiazole ethyl urea inhibitors of DNA gyrase GyrB and topoisomerase IV ParE ATPase **105** and **106**.^[@ref111]^](jm-2014-016846_0012){#fig11}

Dual action benzothiazole ethyl urea based compounds have been explored by Biota, inhibiting the DNA gyrase GyrB and topoisomerase IV ParE ATPase.^[@ref111]^ Two compounds, **105** and **106**, inhibited *C. difficile* 630 (ATCC 9689) at 0.03 and 0.015 μg/mL, respectively (Figure [11](#fig11){ref-type="fig"}).^[@ref111]^ Kibdelomycin, **107**, is a natural product with broad-spectrum antimicrobial activity by inhibiting topoisomerase II ATPase. A 2014 study by Miesel et al. from Merck Research Laboratories examined **107** for in vitro activity against a panel of 168 *C. difficile* clinical isolates (MIC~90~ = 0.25 μg/mL) and other commensal anaerobic organisms.^[@ref112]^ The compound was not orally absorbed and exhibited in vivo efficacy in a hamster model of infection using the toxigenic B1 *C. difficile* strain SM8-6865 (Figure [11](#fig11){ref-type="fig"}).^[@ref112]^

3.9. Peptidic Antimicrobials {#sec3.9}
----------------------------

Pexiganan **108** (Cytolex, MSI-78, Locilex) (structure in Table [2](#tbl2){ref-type="other"}) is a 22-amino-acid antimicrobial peptide with broad-spectrum antimicrobial activity that has recently entered phase III clinical trials under a special protocol assessment as a topically applied treatment of mild infections of diabetic foot ulcers.^[@ref113]^ During development this compound was evaluated for activity against *C. difficile* and was active against four strains of *C. difficile* from 0.5 to 4 μg/mL^[@ref114]^ and again at 4 μg/mL against one other strain of *C. difficile*.^[@ref115]^ A range of 16 cecropin--melittin hybrid peptides (CAMEL analogs) **109**--**124** were also tested against anaerobic bacteria including 10 *C. difficile* strains and were active between 1 and 4 μg/mL (structures in Table [2](#tbl2){ref-type="other"}).^[@ref116]^ However, peptidic antibiotics such as pexiganan **108** and the cecropin--melittin hybrid peptides **109**--**124** are unlikely to survive passage through the gastrointestinal tract.

###### Pexiganan and Cecropin-Melittin Hybrid Peptides[a](#t2fn1){ref-type="table-fn"} with Antimicrobial Activity against *C. difficile*

  peptide              amino acid sequence[b](#t2fn2){ref-type="table-fn"}
  -------------------- -----------------------------------------------------
  pexiganan, **108**   GIGKFLKKAKKFGKAFVKILKK-NH~2~
  CAMEL0, **109**      KWKLFKKIGAVLKVL
  CAMEL9, **110**      KW***R***LFK***N***IGAVLKVL
  CAMEL24, **111**     KWKLFK***H***IGAVLKVL
  CAMEL42, **112**     ***H***WKLFKKIGAVLKVL
  CAMEL46, **113**     KWKLFK***G***I***R***AVLKVL
  CAMEL48, **114**     KWKL***G***KKI***L***AVLKVL
  CAMEL48D, **115**    KWKL***G***KKI***L***AVLKVL
  CAMEL101, **116**    KWKL***G***KKI***LR***VLKVL
  CAMEL102, **117**    ***G***WKL***G***KKI***LR***VLKVL
  CAMEL108, **118**    KWKL***G***KKI***LN***VLKVL
  CAMEL109, **119**    ***G***W***R***L***G***KKI***LR***VLKVL
  CAMEL110, **120**    ***G***WKL***G***KKI***LN***VLKVL
  CAMEL123, **121**    ***L***WKLFKKI***RR***VL***R***VL
  CAMEL129, **122**    ***L***WKLFKKI***NR***VLKVL
  CAMEL135, **123**    ***G***WRL***I***KKI***LR***V***F***K***GL***
  CAMEL136, **124**    ***V***W***R***L***I***KKI***LR***V***F***K***G***L

Adapted from Table [1](#tbl1){ref-type="other"} from OH et al.^[@ref116]^

Bold italicized letters in cecropin--melittin hybrid peptides indicate sites of mutation compared with the CAMEL0 sequence.

Recently, synthetic nylon-3 polymers (poly-β-peptides) **125**--**127** (Figure [12](#fig12){ref-type="fig"}) designed to mimic host-defense peptides were shown to inhibit *C. difficile* growth (MICs of 12.5--25 μg/mL) and importantly also blocked spore outgrowth in two strains of *C. difficile* (MIC of spore outgrowth of 3.13--12.5 μg/mL).^[@ref117]^ Compared to host-defense peptides, synthetic polymer mimics also offer potential advantages for the relative ease of synthesis and stability to proteolytic degradation.

![Nylon-3 polymers **125**--**127**.^[@ref117]^](jm-2014-016846_0013){#fig12}

3.10. Natural Products {#sec3.10}
----------------------

Natural products have a history of use as antibiotics and treatment for *C. difficile* is no exception, with metronidazole, vancomycin, and fidaxomicin all having origins as natural products. A number of more recent, novel natural products investigated for antimicrobial activity against *C. difficile* are described in this subsection.

Ziracin **128** (SCH27899), an oligosaccharide antibiotic derivative of everninomicin, had potent activity against 27 strains of *C. difficile* with MICs ranging from 0.05 to 0.2 μg/mL (Figure [13](#fig13){ref-type="fig"}).^[@ref118]^ The MIC~50~ was 0.1 μg/mL, and MIC~90~ was 0.2 μg/mL.^[@ref118]^ Compound **128** was subsequently tested for activity against a further 25 *C. difficile* strains, with the MIC ranging from 0.06 to 0.125 μg/mL.^[@ref119]^ Although **128** was in development as an iv antibiotic for Gram-positive infections, Schering-Plough suspended development because of failure of efficacy versus safety end points. The two ortho ester linkages in **128** are unlikely to be stable under the acidic conditions of the stomach. Therefore, **128** in itself is not a good lead for oral treatment of CDI without additional measures such as enteric coated capsules.

![Structures of ziracin **128**,^[@ref118]^ hydramycin **129**,^[@ref120]^ clerocidin **130**,^[@ref121]^ echinosporamicin-type antibiotics **131** and **132**,^[@ref123]^ merochlorin A **133**,^[@ref124]^ and olympicin A **134**,^[@ref126]^ and analogs **135**--**138**^[@ref126]^ with activity against *C. difficile*.](jm-2014-016846_0014){#fig13}

Hydramycin **129**, a pyranoanthraquinone isolated from *Streptomyces violaceus*, was shown to have antibiotic and antitumor properties by Bristol Myers Squibb (Figure [13](#fig13){ref-type="fig"}).^[@ref120]^ The activity against one strain of *C. difficile* was 0.4 μg/mL. The cytotoxicity of this antibiotic limits the likelihood of further development, although fidaxomicin also exhibits cytotoxicity.

The natural product clerocidin **130**, a terpenoid antibiotic, displayed potent activity against one *C. difficile* strain with MIC = 0.2 μg/mL.^[@ref121]^ Compound **130** was initially thought to be a DNA gyrase inhibitor,^[@ref121]^ but it has since been shown to act as a DNA alkylating agent that targets single stranded DNA.^[@ref122]^ This mechanism of action limits further use of **130** as an antimicrobial agent.

Two polycyclic antibiotics consisting of a backbone of six fused rings, **131** (TLN-05220) and **132** (TLN-05223), were isolated from *Micromonospora echinospora* ssp. *challisensis* (Figure [13](#fig13){ref-type="fig"}).^[@ref123]^ The echinosporamicin-type antibiotics were potent against various tumor cell lines (IC~50~ of \<0.1 to 9.7 μM depending on the cell line), although **131** failed to show efficacy in an in vivo mouse human prostate tumor model.^[@ref123]^ Both **131** and **132** were active against Gram-positive bacteria *C. difficile*, *S. aureus*, *S. pneumoniae*, and *Enterococcus faecalis*. Compound **131** with a free carboxylic acid was active at 0.06 μg/mL against *C. difficile*, while the methyl ester analogue **132** was less potent with MIC = 2 μg/mL.^[@ref123]^ This compound class would only have use as an anti-*C. difficile* agent if the cytotoxic effects were avoided by poor oral bioavailability.

Merochlorin A **133**, a meroterpenoid, has been investigated for antistaphylococcal and anticlostridial activity (Figure [13](#fig13){ref-type="fig"}).^[@ref124]^ Compound **133** was active at 0.3 and 0.15 μg/mL against two *C. difficile* strains, more potent than the activity against *S. pneumoniae*, multidrug resistant MRSA, and VRE (MICs of 1--4).^[@ref124]^ No activity was observed (MIC of \>64 μg/mL) against Gram-negative strains including *Pseudomonas aeruginosa*, *E. coli*, *Enterobacter cloacae*, *Acinetobacter baumannii*, and *Klebsiella pneumoniae*. However, **133** was cytotoxic against HeLa cells at close to the staphylococcal MIC after extended incubation (IC~50~ = 64 μg/mL at 24 h, IC~50~ = 2 μg/mL at 72 h) and also was inactivated by the presence of 20% human serum (*S. aureus* MIC \> 64 μg/mL).^[@ref124]^ A gram scale synthesis was recently completed, opening up the path for further studies.^[@ref125]^

A collection of natural product flavonoid and related phytochemicals was assessed for their inhibitory action against *C. difficile* in 2014.^[@ref126]^ Olympicin A, **134**, was active at 1 μg/mL against a BI/NAP1/027 *C. difficile* strain, equivalent to vancomycin activity against this strain (Figure [13](#fig13){ref-type="fig"}).^[@ref126]^ Several analogs of **134**, **135**--**138**, containing the natural product chalcone motif, **135**--**137**, or an alternative flavonone core, **138**, were 1--2 dilutions less active against *C. difficile* (Figure [13](#fig13){ref-type="fig"}).^[@ref126]^ Mode of action studies in *S. aureus* showed that **135**--**137** disrupted membrane potential and also inhibited the macromolecular synthesis of proteins, RNA, and DNA.^[@ref127]^ Further analogs have now been reported and evaluated for activity against *Mycobacterium tuberculosis*, *E. faecalis*, *S. aureus*, and *E. coli* but not *C. difficile*.^[@ref127]^

The cyclic thiazolyl derivative **139** (BMS-249524), part of the nocathiacin family, was potent against five strains of *C. difficile* with the MIC activity ranging from 0.06 to 1 μg/mL (Figure [14](#fig14){ref-type="fig"}).^[@ref128]^ Nine analogs of the related thiomuracin A **140**, a thiazolyl actinomycetales metabolite, were also active against *C. difficile* with MICs from 0.003 to ≤0.008 μg/mL (Figure [14](#fig14){ref-type="fig"}).^[@ref137]^ Notably, these compounds are structurally related to **8**, which is in phase II clinical trials as a treatment for *C. difficile* infection.^[@ref65],[@ref129]^

![Cyclic thiazolyl peptidic antimicrobial compounds **139** and **140** similar to **8**, which is in phase II clinical trials.^[@ref128],[@ref129]^](jm-2014-016846_0015){#fig14}

3.11. *C. difficile* Specific Drug Targets and Inhibitors {#sec3.11}
---------------------------------------------------------

Discovery of inhibitors with antimicrobial activity against new drug targets specific to *C. difficile* has so far been limited, in part because of historical difficulties in performing genetic manipulation. The development of the ClosTron gene-knockout system in 2007, which is used to inactive specific genes, has aided essential drug target validation.^[@ref130]^ Potential drug targets for *C. difficile* have been compiled into a database by computational analysis of its genome, searching for choke point enzymes potentially necessary for cell survival, with exclusion of proteins found in human gut microbiota.^[@ref131]^ More recently a curated *C. difficile* metabolic network has been established and used to predict essential targets and potential inhibitors.^[@ref132]^ Validation of these predicted targets and inhibitors is still required. Despite *C. difficile* focused target based drug discovery being in the relative early stages, a number of studies have made progress in this area.

Dang et al. used activity based chemical probes to identify new drug targets in *C. difficile*.^[@ref133]^ They identified Cwp84 as a protease that mediates cleavage of SlpA, required for formation of the surface layer that coats the *C. difficile* cell and important for host--pathogen interactions.^[@ref133]^ No inhibitors have been reported to date.

Ratia et al. attempted to develop selective inhibitors of *C. difficile* by targeting the enzyme dehydroquinate dehydratase (DHQD), which is involved in the shikimate pathway for biosynthesis of chorismate, a precursor required for biosynthesis of three aromatic amino acids.^[@ref134]^ The shikimate pathway is not present in humans, but as DHQD is present in bacteria in two different subtypes, selective inhibitors could potentially be obtained by a target based drug discovery approach. The type I DHDQ is present in *C. difficile*, while the type II DHQD is present in commensal bacterial species such as *Bacteroides thetaiotaomicron* and *Bifidobacterium longum*.^[@ref134]^ The type I *C. difficile* DHQD (*cd*DHQD) was selectively inhibited compared to the type II *B. thetaiotaomicron* DHDQ (*bt*DHDQ) by three compounds **141**--**143** (*cd*DHQD IC~50~ = 31--35 μM, cf. *bt*DHDQ IC~50~ \> 200 μM) identified from high throughput screening efforts (Figure [15](#fig15){ref-type="fig"}).^[@ref134]^ However, the antimicrobial efficacy of the enzyme inhibitors has not yet been reported.

![Inhibitors of type I dehydroquinate dehydratase **141**--**143** (IC~50~ = 31--35 μM).^[@ref134]^ Antimicrobial activity was not reported.](jm-2014-016846_0016){#fig15}

Inhibitors have been developed that inactivate the toxins TcdA and TcdB, but these do not possess antimicrobial activity.^[@ref135],[@ref136]^ Inhibitors of the enzymatic component of binary toxin, CDT, that is expressed by some strains of *C. difficile* have also been investigated.^[@ref137]^ This approach potentially mitigates the disease symptoms, since CDI is a toxin-based disease but is not likely to kill the bacteria themselves. However, by not applying a harsh selection pressure, development of resistance might be prevented.

*C. difficile* spores are a dormant reservoir within the patient or environment that can cause relapsing infection cycles. The *C. difficile* spores sense host signals such as bile salts and amino acid nutrients and germinate into vegetative bacteria that produce toxins and cause disease. Therefore, one potential strategy to prevent relapse is to activate the spores and then eradicate them with an antimicrobial agent. Identification of agents that can promote germination of the entire population of spores, including those in a hyperdormant state, is challenging. This strategy has been explored in vitro whereby osmotic salts were used to activate spores and the antibiotic nisin then inhibited bacterial outgrowth.^[@ref138]^ The identification of agonists of master regulator proteins for spore germination would facilitate this approach. Paradoxically, the opposite approach may also be useful, since blocking germination may prevent colonization and subsequent infection. CspC, a protease, may represent such a target, since it was identified as a bile acid-recognizing germinant receptor and was required for virulence in a hamster model of *C. difficile* infection.^[@ref139]^

3.12. Summary {#sec3.12}
-------------

Antimicrobial agents that previously were considered to lack broad spectrum activity, had poor oral availability, or had systemic toxicity liabilities may be good starting points for further development of new treatments for CDI. In contrast, research into *C. difficile* focused target based drug discovery and therapeutic approaches directed at neutralizing the disease-causing toxins or preventing spore persistence offer new directions to explore. However, there are challenges and limitations associated with the spore-forming and anaerobic nature of *C. difficile* that hamper drug discovery efforts focused on this pathogen. These in vitro and in vivo challenges and limitations, discussed below, must be overcome to progress *C. difficile*-directed new drug discovery.

4. Challenges and Limitations Facing New Drug Discovery {#sec4}
=======================================================

4.1. In Vitro Assays and Challenges {#sec4.1}
-----------------------------------

Discovery of new drugs against *C. difficile* is difficult because of a number of challenges. First, there are technical barriers to general research, as *C. difficile* must be grown under strictly anaerobic conditions, usually in an anaerobic chamber. Specialist equipment and reagents are therefore required to meet these basic growth conditions, with the outright cost of these items, together with maintenance and consumable costs, being prohibitive to a nonspecialist laboratory. Anaerobic microbiology skills are also required, although stepwise protocols for laboratory maintenance of *C. difficile* and prevention of culture contamination with spores when handling multiple strains are available.^[@ref140],[@ref141]^ Industry--academic collaborations are providing a path for advancing compound development as difficulties, and costs associated with establishing the specialist infrastructure and in-house expertise can be overcome.

The awkwardness of manipulating cultures inside an anaerobic chamber limits throughput, as does the size of the incubator compared to standard large shaker incubators available for bacteria grown aerobically. The agar dilution technique remains the gold standard for anaerobic susceptibility testing of anaerobes recommended by NCCLS.^[@ref142]^ However, agar dilution has several limitations for *C. difficile*-specific drug discovery. First, it limits the number of compounds that can be tested at any one time because of the large amount of incubator space required when each compound is tested at numerous concentrations. Agar dilution also requires a larger amount of test compound for preparing the agar, compared to high throughput 96-well or 384-well broth microdilution assays. This can be prohibitive when the compound is only available in milligram quantities or when compound libraries or many analogs need to be tested. Therefore, the agar dilution method favors investigation of a limited number of lead compounds, which can be tested against multiple strains spotted on the same agar plate concurrently, rather than allowing large compound libraries or a large number of synthesized analogs to be screened. A better alternative for this purpose is microdilution susceptibility testing which only uses a fraction of the amount of compound required for the agar dilution method. Note that the disk diffusion method tends not to be used as often as agar dilution or broth microdilution.

*C. difficile* spores are critical to *C. difficile* disease etiology, and the infection cycle and must be considered in the evaluation of potential of new drug candidates. It is reasonable to assume that to target vegetative and spore forms, different physicochemical properties for cellular entry and even different compound targets are likely to be required. During CDI, in an in vivo context, *C. difficile* exists as a mixed population of vegetative bacteria and spores. Therefore, testing that is confined to the vegetative bacterial form or isolated spores does not represent the situation in vivo. Adding to this complexity is the recent demonstration that *C. difficile* forms biofilms,^[@ref143]^ which adds a further hurdle to effective antibiotic treatment and therapeutic development. Spore formation, germination, and outgrowth are highly regulated processes that shift according to growth phase, nutrient availability, and other host-specific selection pressures such as antibiotic treatment and the presence of competing bacteria. To address the effectiveness of compounds at each stage of the *C. difficile* life cycle, separate assays studying sporulation, germination, and vegetative cell outgrowth are required.^[@ref144]−[@ref146]^ However, performing each of these assays in a high throughput manner to keep up with medicinal chemistry efforts is challenging. Adding to this difficulty is the unreliable sporulation of *C. difficile* in liquid media, with significant difficulties encountered in attempts to reproducibly synchronize sporulation during in vitro growth.^[@ref18]^

Given the physiological limitations of standard in vitro testing of organisms in a single microbe culture system that does not contain competing microbiota, microbial fermentation products, or bile salts, all of which influence *C. difficile* growth, sporulation, and germination, alternative models have been developed that more closely resemble the host environment. These in vitro gut models involve a single continuous culture reactor, a more complex three-tier system, or a scaled down minibioreactor. The bioreactor is inoculated with a human fecal suspension, treated with antibiotic(s) to model the initial infection susceptibility disease stage, and then challenged with *C. difficile* spores or vegetative cells to initial infection. Culture samples can be taken over the course of the growth period, and *C. difficile* total cell counts and spore counts are enumerated using selective agar media. A metagenomic sequencing approach can be used to study changes in the diversity of the microbial populations, which overcomes the problem posed by the presence of uncultivable microbes in this type of analysis.

The three-tier system models the increasing alkalinity found through the gastrointestinal tract in three stages. The effectiveness of oritavancin,^[@ref147]^**6**,^[@ref148]^ and cadazolid^[@ref149]^ has been evaluated in this system, showing the effect of antibiotic treatment on vegetative and spore *C. difficile* bacterial numbers as well as the relative numbers of the indigenous bacteria over time.^[@ref147],[@ref148],[@ref150]^ More recently, the three-tier system model has been modified to study *C. difficile* biofilm formation in the context of the gut microbiota environment and antibiotic treatment.^[@ref151],[@ref152]^ One disadvantage of the three-tier model is the time required to complete experiments, which are of 6--8 weeks duration, thereby limiting compound throughput. Therefore, despite the potentially useful culture and microbiome information that this model can provide, this system is limited to the evaluation purposes conducted in the late stages of compound development and it is difficult to envision how it can be applied to high throughput screens of large numbers of analogs. The single reactor is a simplified version of the three-tier reactor, which may provide more utility for this purpose. Scaled down minibioreactors, located inside an anaerobic chamber, offer the advantage of being able to test multiple antibiotics at different concentrations at the same time. Once again, monitoring the microbiome community at the population level can be achieved using genome sequencing technologies.

4.2. Advantages and Limitations of Animal Infection Models {#sec4.2}
----------------------------------------------------------

Animal infection models are critical for the assessment of drug candidate efficacy, since the contribution of many host factors to disease complexity, such as the immune response, simply cannot be reproduced in vitro. They also allow gross toxicities that may not be apparent through in vitro toxicity assays to be determined and are also essential for downstream regulatory body approval processes. The gold standard *C. difficile* infection model has been the hamster model (comprehensive review by Best et al).^[@ref153]^ However, one disadvantage of the hamster model is that disease takes place at a different site of infection (cecum compared to colon for humans). Furthermore, disease symptoms do not closely mimic those of humans, since the infection does not typically cause diarrhea and almost always leads to death in hamsters as a result of their exquisite sensitivity to the *C. difficile* toxins. The typical human CDI disease spectrum is not represented in this model, and antimicrobial efficacy can only be assessed in the context of prevention of death. Nevertheless, a wide range of antimicrobials and drug candidates have been evaluated and shown to be effective against *C. difficile* in the hamster model including rifaximin,^[@ref154]^ fidaxomicin,^[@ref155]^**5**,^[@ref156]^ cadazolid,^[@ref157]^ ramoplanin,^[@ref158]^ nitazoxanide,^[@ref159]^ rifalazil,^[@ref160]^ and oritavancin.^[@ref161]^

The more recently developed mouse CDI models appear to correlate more closely with human CDI (recently reviewed by Hutton et al.)^[@ref162]^ Importantly, mouse antibiotic treatment CDI induction regimes can be tailored to yield different disease outcomes. Treatment with single antibiotics, such as clindamycin, results in mice that reproducibly develop a mild, nonfatal disease upon infection. By contrast, mice treated with a mixture of broad-spectrum antibiotics develop a severe, often fatal disease following infection.^[@ref162]^ The ability to modulate disease severity, presumably through differential effects on host microbiota depending on the antibiotic treatment regime, allows flexibility in the assessment of new therapeutics on disease stages representing the spectrum seen in human CDI. The smaller size of mice also means that less compound is required for testing, which is an important consideration in the early stages of compound development.

Additional advantages of using mouse rather than hamster infection models include the greater ease of scoring disease symptoms such as weight loss and diarrhea as well as the ability to use the diverse range of mouse-specific reagents available for immunohistological tissue or other assessments. Furthermore, disease transmission^[@ref163]^ and relapse models^[@ref164]^ have been developed that allow these aspects of disease to be studied. Although the latter model does not allow relapse versus reinfection to be distinguished, both of which are likely to be important in recurrent human infection, it does provide a tool that can be used to determine how effective a treatment is in eradicating recurrent infection within the host following a primary infection. The variation between human and animal gut microbiomes must also be considered when animal models are used to test new antimicrobial compounds, since CDI susceptibility hinges on the host microbiome. However, next generation sequencing provides a powerful tool to evaluate these differences and the effect of treatments on microbial populations, providing unique opportunities that will lead to a better understanding of the complex host--microbial interactions that occur during CDI. Such efforts are also focused on understanding what microbiome community structures constitute "healthy", "susceptible", and "disease" states, which will also provide insights into our understanding of CDI.

Finally, it is important to consider which *C*. *difficile* strains are used in animal infection and CDI treatment studies. Recent epidemiological and genome sequencing studies have shown that *C*. *difficile* is a genetically heterogeneous species and that new variants are detected regularly, some of which cause epidemics.^[@ref7],[@ref165]^ For example, these studies demonstrated that the epidemic BI/NAP01/027 group comprises two independently arisen lineages of fluoroquinolone resistant strains that spread globally^[@ref7]^ and that diverse strains of unknown origin cause CDI,^[@ref165]^ illustrating how new technologies can provide important insights into disease transmission and evolution on a population scale.^[@ref7]^ In the context of drug discovery, it is important to include a variety of strains in compound testing to assess their effectiveness across the range of *C*. *difficile* strain variants, especially at the lead optimization stage. These therapeutic agents must be effective against diverse strains, or selective forces will favor the proliferation and dissemination of strains against which the compound is least effective.

5. Conclusion {#sec5}
=============

In the past 10 years *C. difficile* has become a significant threat to human health. Even with the recent launch of the *C. difficile*-targeted antibiotic fidaxomicin, there is still no antibiotic available that can completely prevent recurrent disease. There remains an unmet need for better treatments that prevent relapse and reinfection, as well as transmission. To address this need, the scientific and medical communities are developing new treatment agents from both small molecule and biotherapeutic approaches. Selective antibiotics that do not destroy the diversity of microbiota associated with gut homeostasis and that *also* effectively inhibit spore formation are required. Nonorally absorbed agents, stable to passage through the stomach and small intestine, are desirable to maintain high concentrations of antibiotic at the site of infection, thus minimizing systemic toxicity and reducing the possibility of treatment failure due to MIC creep associated with antimicrobial resistance. Reinvestigation of abandoned antimicrobial lead candidates and analogs for their ability to fit the target product profile above, as occurred to bring the long ago discovered fidaxomicin out of the shadows and to market in 2011, offers one avenue toward the development of new drugs to fight CDI. Meanwhile, as *C. difficile* gains ground as a superbug to be reckoned with, further investment into understanding the biology of this organism and the subsequent identification of new drug targets will provide opportunities for medicinal chemists to develop first-in-class antimicrobials using target based drug discovery approaches. Other nonantibiotic treatment approaches such as vaccines and monoclonal antibiotics in clinical trials offer hope for another strategy to combat CDI and if successful could change the landscape of *C. difficile* research and development. The restoration of damaged gut microbiota using bacteriotherapy, whether fecal transplant or microbial ecosystem replacement, and as a treatment, adjunct therapy, or prophylactic offers great promise as a nonantibiotic therapy. The growing understanding of the complex gut microbe interactions and identification of which bacterial populations need to be maintained for good health will influence the development of new drugs. While concerns remain over the long-term health effects of bacteriotherapy, *C. difficile* drug discovery remains challenging because of the complex disease etiology and the technical challenges inherent with recurrence and relapse in predictive in vivo animal models. Looking forward, a combination of selective antibiotic *and* microbial restorative treatment may prove a winning formula.

Methods for clustering ChEMBL data and Table 1 listing summary of single drug candidates tested against *C. difficile*. This material is available free of charge via the Internet at <http://pubs.acs.org>.
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